Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Peak Bio, Inc.

Peak Bio, Inc. develops innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Peak Bio Inc. | 789 followers on LinkedIn. Clinical-stage biopharmaceutical company. #PKBO | Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Notice to recruiters

All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees.

In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department. 

pH Pharma Inc. Director

신용남

Associate Director at pH Pharma Co., Ltd.

	Dec '21	Dec '22	Dec '23
revenue	528.31K -	607.68K 15.02%	367.88K 39.46%
cost of revenue		-607.68B -
gross profit	528.31K -	607.68B 115,023,683.43%	367.77K 100.00%
selling and marketing expenses
general and administrative expenses	2.47M -	8.53M 245.43%
selling general and administrative expenses	2.47M -	8.53M 245.43%
research and development expenses	7.12M -	3.92M 44.92%	1.63M 58.53%
other expenses		-819.06K -
cost and expenses	9.59M -	12.46M 29.83%
operating expenses	9.59M -	12.46M 29.83%	1.35K 99.99%
interest expense	11.47K -	47.96K 318.08%	-2.73M 5,788.52%
ebitda	-8.89M -	-11.88M 33.63%
operating income	-9.07M -	-11.85M 30.69%
depreciation and amortization	176.81K -	-30.46K 117.23%
total other income expenses net	855.02K -	-1.31M 253.78%
income before tax	-8.21M -	-13.16M 60.32%
income tax expense	82.07K -	-74K 190.17%
net income	-8.29M -	-13.09M 57.84%	-1.26K 99.99%
weighted average shs out	17.16M -	17.71M 3.20%	87.10K 99.51%
weighted average shs out dil	17.16M -	17.71M 3.20%	87.10K 99.51%
eps	-0.48 -	-0.74 54.17%	-0.01 98.04%
epsdiluted	-0.48 -	-0.74 54.17%	-0.01 98.04%

COM:PEAK-BIO

Peak Bio, Inc.

Last Close

0.05

14/11 20:00

Market Cap

192.60K

Beta: -

Volume Today

1.93K

Avg: -

Preview